Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director Dealing
London, September 20, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on September 19, 2019, Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 13,500 Ordinary Shares at a price of GBP0.59 per share.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
|
1 |
Details of the person discharging managerial responsibilities |
|||||
|
a) |
Name |
Denise Scots-Knight |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Executive Officer |
||||
|
b) |
Initial notification/ Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mereo BioPharma Group plc |
||||
|
b) |
LEI |
213800U8JQHIJOS5AS09 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument and identification code |
MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
|
||||
|
b) |
Nature of the transaction |
PURCHASE |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information: volume, Price |
Aggregated volume: 13,500 Aggregated price: GBP0.59 |
||||
|
e) |
Date of the transaction |
2019-09-19 |
||||
|
f) |
Place of the transaction |
AIMX |
||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
